

Converge Biotech, OncoDNA offer personalised cancer care

09 February 2021 | News

OncoDNA's solutions are designed to guide oncologists in the selection of the most appropriate treatments based on the specific tumour profile of a patient

Converge Biotech, a leading healthcare organisation based in Hyderabad has announced that it has entered into a long-term strategic alliance with OncoDNA, a Belgium-based theranostic and genomic company specialising in precision oncology, to personalise care for late-stage cancer patients across India. OncoDNA's solutions are designed to guide oncologists in the selection of the most appropriate treatments based on the specific tumour profile of a patient.

With the aim of improving the clinical outcomes of patients living with advanced solid tumours such as breast or lung cancers, Converge Biotech will provide physicians and healthcare providers across India with OncoDNA's portfolio of comprehensive diagnostic solutions that include:

- OncoDEEP: Comprehensive biomarker test combining DNA, RNA and protein analyses on a tumour tissue
- OncoSTRAT & GO: Unique biomarker test combining analysis on liquid and solid biopsies
- OncoSELECT: Smart cancer-specific profiling solution analysing ctDNA in a liquid biopsy
- OncoFOLLOW: Personalised liquid biopsy for patient monitoring

Briefing about the alliance, Arun Kumar Bijjala, Managing Director, Converge Biotech Pvt Ltd said, "Our foray into specialised diagnostic services in the oncology domain extends our vision of enabling medical community to make informed decisions and ensure better treatment outcomes."

Corina Cucuruzac, Head, Global Distribution, OncoDNA stated, "Giving oncologists access to cancer biomarker testing is key to improve the treatment journey of patients living with cancer. We are delighted to have found in Converge Biotech a trusted partner to support together with the adoption of precision medicine for the benefit of cancer patients in India."